Swiss National Bank held its position in Arrowhead Research Corp. (NASDAQ:ARWR) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 91,400 shares of the company’s stock at the end of the second quarter. Swiss National Bank owned 0.15% of Arrowhead Research Corp. worth $486,000 at the end of the most recent reporting period.
Several other institutional investors have also recently bought and sold shares of ARWR. Falcon Point Capital LLC increased its stake in Arrowhead Research Corp. by 12.5% in the second quarter. Falcon Point Capital LLC now owns 49,147 shares of the company’s stock worth $261,000 after buying an additional 5,458 shares during the last quarter. Bank of New York Mellon Corp increased its stake in Arrowhead Research Corp. by 7.1% in the second quarter. Bank of New York Mellon Corp now owns 290,559 shares of the company’s stock worth $1,547,000 after buying an additional 19,376 shares during the last quarter. California State Teachers Retirement System increased its stake in Arrowhead Research Corp. by 0.7% in the second quarter. California State Teachers Retirement System now owns 126,906 shares of the company’s stock worth $675,000 after buying an additional 852 shares during the last quarter. Finally, Quantitative Investment Management LLC bought a new stake in Arrowhead Research Corp. during the second quarter worth about $132,000. 33.97% of the stock is owned by institutional investors and hedge funds.
Arrowhead Research Corp. (NASDAQ:ARWR) traded down 0.15% on Monday, hitting $6.63. 236,621 shares of the stock were exchanged. The company’s market cap is $402.77 million. The company’s 50 day moving average price is $7.13 and its 200-day moving average price is $6.14. Arrowhead Research Corp. has a one year low of $3.07 and a one year high of $8.22.
Arrowhead Research Corp. (NASDAQ:ARWR) last posted its quarterly earnings data on Tuesday, August 9th. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.05. Arrowhead Research Corp. had a negative net margin of 48,980.81% and a negative return on equity of 100.50%. The company earned $39.58 million during the quarter, compared to analyst estimates of $0.05 million. During the same period in the prior year, the firm earned ($0.27) earnings per share. The business’s quarterly revenue was down 68.0% on a year-over-year basis. Equities research analysts predict that Arrowhead Research Corp. will post ($1.31) EPS for the current fiscal year.
A number of equities research analysts recently issued reports on the stock. Chardan Capital restated a “buy” rating and issued a $10.00 target price on shares of Arrowhead Research Corp. in a report on Wednesday, September 7th. William Blair started coverage on shares of Arrowhead Research Corp. in a report on Friday, August 19th. They issued an “outperform” rating for the company. Cantor Fitzgerald reiterated a “buy” rating and set a $15.00 price objective on shares of Arrowhead Research Corp. in a research note on Thursday, September 29th. Finally, Piper Jaffray Cos. decreased their price objective on shares of Arrowhead Research Corp. from $13.00 to $8.00 and set an “overweight” rating for the company in a research note on Wednesday, August 10th. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. Arrowhead Research Corp. currently has a consensus rating of “Buy” and an average target price of $10.11.
In other Arrowhead Research Corp. news, CFO Kenneth Allen Myszkowski sold 13,100 shares of the company’s stock in a transaction dated Monday, August 22nd. The shares were sold at an average price of $8.00, for a total transaction of $104,800.00. Following the completion of the sale, the chief financial officer now directly owns 128,789 shares of the company’s stock, valued at $1,030,312. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 3.90% of the company’s stock.
Arrowhead Research Corp. Company Profile
Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, is a biopharmaceutical company. The Company is engaged in developing RiboNucleic Acid interference (RNAi) therapeutics. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA. ARC-520 is designed to treat chronic hepatitis B virus (HBV) infection.
Want to see what other hedge funds are holding ARWR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arrowhead Research Corp. (NASDAQ:ARWR).
Receive News & Ratings for Arrowhead Research Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Research Corp. and related companies with MarketBeat.com's FREE daily email newsletter.